The time between FoxP3 expression in the RPE and onset of clinical signs of geographic atrophy is currently not known in humans, but is expected to be individually variable due to the differences in lifestyle and genetic background, which could explain the lack of FoxP3 in aged, but healthy human eyes. Here, FOXP3 is linked to atrophic macular degeneration.